Vaxcell-Bio Therapeutics Co., Ltd.

KOSDAQ:A323990 Stock Report

Market Cap: ₩320.1b

Vaxcell-Bio Therapeutics Balance Sheet Health

Financial Health criteria checks 6/6

Vaxcell-Bio Therapeutics has a total shareholder equity of ₩78.3B and total debt of ₩0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are ₩83.1B and ₩4.9B respectively.

Key information

0%

Debt to equity ratio

₩0

Debt

Interest coverage ration/a
Cash₩49.60b
Equity₩78.27b
Total liabilities₩4.87b
Total assets₩83.14b

Financial Position Analysis

Short Term Liabilities: A323990's short term assets (₩52.1B) exceed its short term liabilities (₩2.3B).

Long Term Liabilities: A323990's short term assets (₩52.1B) exceed its long term liabilities (₩2.5B).


Debt to Equity History and Analysis

Debt Level: A323990 is debt free.

Reducing Debt: A323990 has no debt compared to 5 years ago when its debt to equity ratio was 8820.2%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: A323990 has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: A323990 has sufficient cash runway for 2.4 years if free cash flow continues to reduce at historical rates of 24.3% each year.


Discover healthy companies